Related Experiment Video
Updated: Oct 27, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Mucha-Habermann disease: a pediatric case report and proposal of a risk score
Martin Ernst Blohm1,2, Chinedu Ulrich Ebenebe1,2, Cornelius Rau1,2
1Department of Paediatrics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract:
Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is a rare inflammatory dermatological disease. A case of a 13-year-old boy with FUMHD possibly triggered by mycoplasma infection is presented. Based on FUMHD cases identified in a MEDLINE literature search, demographic, treatment, and outcome data were analyzed. An FUMHD mortality risk score is proposed based on the likelihood ratios of risk factors for a fatal outcome. Our FUMHD case had marked leukopenia and thrombocytopenia at admission. He recovered without systemic immunosuppressive treatment. Literature review revealed 119 FUMHD cases. Overall lethality was 14/119 (12%, CI 6-17%), and lethality in children was lower (1/54, 2%, CI 0-6%) compared to adults (13/65, 20%, CI 11-31%). Risk factors for a fatal outcome (likelihood ratio; P) were sepsis (24.97, P < 0.001), adult vs. pediatric patient age (11.19; P = 0.001), systemic involvement (19.97, P < 0.001), and mucosal involvement (4.58; P = 0.032). The proposed FUMHD mortality risk score = Age/10 + 4 + 4 (if systemic involvement) + 1 (if mucosal involvement) was discriminative (sensitivity 93%, specificity 77%). In FUMHD, immune-suppressive treatment intensity should be balanced against the mortality risk, as infectious complications are a frequent cause of death.
Insights
Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is rare. A new mortality risk score helps balance treatment intensity against risks like sepsis, especially in adults, guiding better patient outcomes.
Area of Science:
- Dermatology
- Immunology
- Epidemiology
Background:
- Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is a severe, rare inflammatory dermatological condition.
- Understanding FUMHD's epidemiology and risk factors is crucial for effective management.
Observation:
- A case study of a 13-year-old boy with FUMHD, potentially triggered by Mycoplasma infection, highlights clinical presentation.
- The patient experienced leukopenia and thrombocytopenia but recovered without systemic immunosuppression.
Findings:
- Literature review of 119 FUMHD cases revealed an overall lethality of 12%, with significantly higher mortality in adults (20%) than children (2%).
- Key risk factors for fatal outcomes include sepsis, adult age, systemic involvement, and mucosal involvement.
- A novel FUMHD mortality risk score was developed, demonstrating high sensitivity (93%) and specificity (77%) in predicting fatal outcomes.
Implications:
- The proposed FUMHD mortality risk score aids clinicians in tailoring immunosuppressive treatment intensity.
- Balancing treatment against mortality risks, particularly infectious complications, is vital for improving FUMHD patient survival.
- Further research into FUMHD triggers, like Mycoplasma infections, could inform preventative strategies.
Related Concept Videos
Hazard Ratio
For example, in a clinical trial...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Relative Risk
Hazard Rate

